FR-008-III
FR-008-III Brand names, FR-008-III Analogs
FR-008-III Brand Names Mixture
- No information avaliable
FR-008-III Chemical_Formula
C12H17NO2
FR-008-III RX_link
http://www.rxlist.com/cgi/generic3/penlac.htm
FR-008-III fda sheet
FR-008-III msds (material safety sheet)
FR-008-III Synthesis Reference
No information avaliable
FR-008-III Molecular Weight
207.269 g/mol
FR-008-III Melting Point
144 oC
FR-008-III H2O Solubility
No information avaliable
FR-008-III State
Solid
FR-008-III LogP
2.33
FR-008-III Dosage Forms
Topical solution (8%)
FR-008-III Indication
Used as a topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum.
FR-008-III Pharmacology
Ciclopirox is a broad-spectrum antifungal medication that also has antibacterial and anti-inflammatory properties. Its main mode of action is thought to be its high affinity for trivalent cations, which inhibit essential co-factors in enzymes. Ciclopirox exhibits either fungistatic or fungicidal activity in vitro against a broad spectrum of fungal organisms, such as dermatophytes, yeasts, dimorphic fungi, eumycetes, and actinomycetes. In addition to its broad spectrum of action, ciclopirox also exerts antibacterial activity against many Gram-positive and Gram-negative bacteria. Furthermore, the anti-inflammatory effects of ciclopirox have been demonstrated in human polymorphonuclear cells, where ciclopirox has inhibited the synthesis of prostaglandin and leukotriene. Ciclopirox can also exhibit its anti-inflammatory effects by inhibiting the formation of 5-lipoxygenase and cyclooxygenase.
FR-008-III Absorption
Rapidly absorbed after oral administration. Mean absorption of ciclopirox after application to nails of all twenty digits and adjacent 5 millimeters of skin once daily for 6 months in patients with dermatophytic onychomycoses was less than 5% of the applied dose. Ciclopirox olamine also penetrates into hair and through the epidermis and hair follicles into sebaceous glands and dermis.
FR-008-III side effects and Toxicity
Oral LD50 in rat is >10 ml/kg. Symptoms of overexposure include drowsiness and headache.
FR-008-III Patient Information
No information avaliable
FR-008-III Organisms Affected
Humans, other mammals, yeast and other fungi
